Recent

% | $
Quotes you view appear here for quick access.

Spectrum Pharmaceuticals, Inc. Message Board

  • stringandtwocups stringandtwocups Feb 21, 2013 7:19 AM Flag

    looks to me like shorty theory "demise of fusilev" has been debunked.......expect higher analyst price targets

    fusilev unit sales increased from q3 to q4..............fusilev is going to remain a cash cow for sppi whether it be 40 mill/qtr revenue or 65 mill/qtr per quarter............ meanwhile 135 million cash savings AFTER allos acquisition costs......... pipeline clinical trials funded by fusilev..........and folotyn since acquired by sppi seems to be on track for historically best revenues going forward............ will be a very positive conference call. analysts will have to try hard not to issue notes to effect sppi pps is grossly undervalued. looking for new higher ratings from credit suisse and higher price targets from all covering analysts.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
SPPI
4.63-0.10(-2.11%)1:34 PMEDT